https://mededonthego.com/news/adi-270-gains-fda-fast-track-status-in-metastaticadvanced-ccrcc/2467343/
ADI-270 Gains FDA Fast Track Status in Metastatic/Advanced ccRCC - MedEd On The Go
A fast track designation has been given to ADI-270 from the FDA for treating metastatic or advanced clear cell renal cell carcinoma (ccRCC) previously tre…
fda fast trackon the goadigainsstatus
https://ecancer.org/en/video/11796-subcutaneous-delivery-of-nivolumab-is-effective-in-treating-metastatic-ccrcc
Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC - ecancer
Dr Saby George speaks to ecancer about the pharmacokinetics, efficacy, and safety results from CheckMate 67T trial. This study evaluated the pharmacokinetics
subcutaneousdeliverynivolumabeffectivetreating
https://touchoncology.com/insight/reversing-vegf-tki-resistance-in-ccrcc-early-data-from-the-fit-001-trial/?_rt=M3wxfGVhdXwxNzkxMDgyODQ5&_rt_nonce=52f3966fd4
Reversing VEGF TKI resistance in ccRCC: Early data from the FIT-001 trial - touchONCOLOGY
New clinical data presented at the 2026 International Kidney Cancer Symposium (IKCS) Europe supports the potential of next-generation FTI darlifarnib, alone...
early datafrom thereversingvegftki
https://onco-hema.healthbooktimes.org/article/121111-writing-history-in-the-adjuvant-treatment-of-clear-cell-renal-cell-carcinoma-ccrcc-the-magic-goal-of-an-overall-survival-benefit-was-reached-as-rep
Writing History in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC): The Magic...
By Ursula Vogl. This commentary by PD Dr Ursula Vogl covers an update in the adjuvant treatment of clear cell renal cell carcinoma from the ASCO GU 2024.
writing historyadjuvant treatmentclear cellrenal carcinomaccrcc